Design and Synthesis of Bioactive Compounds

Message from the Guest Editor

Dear Colleagues,

Many drugs available today were discovered by chance. Drug design is aiming to invent and develop novel biologically-active molecules (leads) for targets (e.g., enzyme, receptor, cell, tissues, etc.) in therapeutic areas. For developing such potential leads all known theoretical and experimental knowledge of the physiological targets is applied. Most commonly, these targets are enzymes and thus enzyme inhibitors account for many of the drugs on today’s market and cover many different therapeutic areas. This issue will cover all remaining techniques of drug design, including: rationale search for novel scaffold, computer-aided design, use of multicomponent chemistry, structural analogy approach, structural and topographical mimetics, multitarget drug design including drug repurposing, natural product-based drugs, etc.

Prof. Dr. Paweł Kafarski
Guest Editor
Editor-in-Chief

Dr. Derek J. McPhee
Senior Director, Technology Strategy, Amyris, Inc., 5885 Hollis St, Suite 100, Emeryville, CA 94608, USA

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 22nd year of publication, the papers published in Molecules span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed), Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 12.6 days after submission; acceptance to publication is undertaken in 4.4 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Molecules
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/molecules
molecules@mdpi.com
@Molecules_MDPI